The Global Rx Medical Food Market, by product type (pills, powders, liquids, and others (wafers, chewables and bars)), by therapeutic application (pain management, sleep disorder, neurological disorder, GI disorder, pulmonary disorders, metabolic disorders, and others (fibrosis, dialysis, aids, etc.)), by distribution channel (retail pharmacies and online pharmacies), and by region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 14,504.6 million in 2016 and is projected to exhibit a CAGR of 7.0% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Growing regulatory support, increasing awareness about medical food in emerging economies and advantages over drug therapies are expected to be the major factors driving growth of the global Rx medical food market over the forecast period.
Manufacturers are developing medical food products with improved therapeutic effects and different dosage forms for ease of administration and patient convenience. Abbott laboratories introduced science-based nutrition drinks, Ensure Surgery Immunonutrition Shake, and Ensure Pre Surgery Clear Nutrition in 2016, to help patients recover from surgeries. Cera Products, Inc. launched Ceralyte oral rehydration salt to treat dehydration and diarrhea in 2017. Cambrooke announced the launch of Tylacti COMPLETE Bars, a nutritionally complete medical food available in a convenient format, for the dietary management of Tyrosinemia (TYR) in 2017. The company launched medical food line Phenactin AA Plus, Vilactin AA Plus, Isovactin AA Plus, Homactin AA Plus, and Promactin AA Plus for inborn errors of metabolism in 2015. Nutricia Metabolics launched Anamix Next for Tyrosinemia, Methylmalonic Acidemia, and Isovaleric Acidemia in 2015. Moreover, the company launched PhenylAde GMP, a new formula for Phenylketonuria (PKU) in the same year.
Some major players operating in the Rx medical food market include Abbott Laboratories, Danone, Mead Johnson & Company, LLC, Fresenius Kabi AG, Nestle, Primus Pharmaceuticals, Inc., Targeted Medical Pharma, Enzymotec ltd., AlfaSigma, and Pivotal Therapeutics.
Get Sample Copy at https://www.coherentmarketinsights.com/insight/request-sample/909
Browse 40 Market Data Tables and 35 Figures spread through 166 Pages and in-depth TOC on Rx medical food market, by product type (pills, powders, liquids, and others (wafers, chewables and bars)), by therapeutic application (pain management, sleep disorder, neurological disorder, GI disorder, pulmonary disorders, metabolic disorders, and others (fibrosis, dialysis, aids, etc.)), by distribution channel (retail pharmacies and online pharmacies), and by region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2025
Key players are investing in research and development activities of pipeline products for the development of novel medical food that can be used in various medical conditions. For instance, in 2012, Targeted Medical Pharma reported preliminary data of its new amino acid-based oral formulation called PERCURA, which can be used for reducing symptoms of pain and numbness associated with peripheral neuropathy, in an open-label pilot study. In 2015, Enzymotec Ltd announced investigator initiated clinical trial of Vayarin, which is capable of managing attention deficit hyperactivity disorder (ADHD) in children suffering from epilepsy. Moreover, scientists at Nestlé Institute of Health Science are studying human DNA for the development of personalized programs for epilepsy and intestinal disorders, thereby leading to development of medical food products that contain natural compounds.
Major players are adopting strategies such as mergers and acquisitions to expand their product portfolio and enter into the medical food industry. Nestlé is adding medical foods such as prescription-based powders and drinks that can be used for treatment of diseases to its existing product portfolio for business expansion, which will in turn help the company to enter the nutrition sector. In 2017, AlfaSigma, an Italy-based company completed the acquisition of the U.S. medical food maker Pamlab from Nestlé, to strengthen the company’s operations in North America. The U.S. Food & Drug Administration (FDA) awarded grants through the Orphan Products Clinical Trials Grants Program, to encourage clinical development of products, which includes medical food to treat rare diseases or conditions.
Key Takeaways of the Rx Medical Food Market:
The global Rx medical food market is expected to exhibit a CAGR of 0% over the forecast period (2017–2025), owing to the presence of high potential, especially in Asia Pacific, Latin America, the Middle East, and Africa
Novel product developments for varying disease conditions and increasing awareness about the health benefits of medical food is expected to drive growth of the global Rx medical food market
The U.S. congress has passed a National Defense Authorization Act in 2017, to cover costs of medical food under Tricare (military healthcare). This step is expected to support patients suffering from medical conditions and consuming medical food. This category was previously not covered for reimbursement under prescription drug plans.
Table of Contents
Research Objective and assumption
Market Dynamics, Regulations, and Trends Analysis
Global Rx Medical Food Market, By Product Type, 2017 – 2025 (US$ Mn)
Global Rx Medical Food Market, By Therapeutic Application , 2017 – 2025 (US$ Mn)
Global Rx Medical Food Market, By Distribution Channel, 2017 – 2025 (US$ Mn)
Global Rx Medical Food Market, By Regions, 2017 – 2025 (US$ Mn)
Purchase Rx Medical Food Market Report at https://www.coherentmarketinsights.com/insight/buy-now/909
Company Name: Coherent Market Insights
Contact Person: Mr. Shah
Email: Send Email
Address:1001 4th Ave, #3200
Country: United States